Ospedale San Raffaele

Running trials

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· Source

• Not yet recruiting

  AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation

  NCT07604727· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Source

• Recruiting

  A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

  NCT07483099· Phase 2· Source

• Not yet recruiting

  This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life Based on the Treatment Received in the Group of Patients Suffering From Malignant Lesions of the Head and Neck

  NCT07066878· Source

• Recruiting

  InRAD Observational Study

  NCT07213700· Source

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Source

• Recruiting

  A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy

  NCT07595653· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Source

• Recruiting

  A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes

  NCT07203768· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Source

• Recruiting

  Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  NCT07106762· Phase 2/3· Source

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Source

• Recruiting

  A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  NCT06876662· Phase 4· Source

• Recruiting

  A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  NCT06876649· Phase 4· Source

• Recruiting

  The Dragon PLC Trial (DRAGON-PLC)

  NCT06914648· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Source

• Recruiting

  Landiolol in Mitral Valve Surgery

  NCT06793670· Phase 4· Source

• Recruiting

  FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

  NCT06733038· Phase 3· Source

• Active, not recruiting

  Abbott Medical - VERITAS Study

  NCT06707688· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Source

• Recruiting

  Reduction of Mitral Regurgitation With the SATURN Trans-Septal Transcatheter Mitral Valve Replacement (TMVR) System in Patients With Severe Symptomatic Mitral Regurgitation

  NCT06414265· Source

• Active, not recruiting

  First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

  NCT06239467· Phase 1· Source

• Recruiting

  CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

  NCT06037980· Phase 2/3· Source

• Active, not recruiting

  A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

  NCT05776472· Source

• Recruiting

  Dissecting the Molecular and Cellular Pathophysiology of Sarcopenic Obesity in the Elderly

  NCT06320158· Source

• Active, not recruiting

  An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

  NCT05876754· Phase 3· Source

• Recruiting

  Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis

  NCT06318598· Source

• Recruiting

  Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

  NCT05496998· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Source

• Active, not recruiting

  Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

  NCT05169567· Phase 3· Source

• Recruiting

  Study on the Diagnosis and Management of CLL in Italy by GIMEMA

  NCT04867915· Source

• Recruiting

  A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  NCT05006716· Phase 1/2· Source

• Active, not recruiting

  Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants

  NCT04964271· Source

• Recruiting

  Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis

  NCT06413459· Source

• Recruiting

  Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

  NCT04373564· Phase 4· Source

• Active, not recruiting

  Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

  NCT04561362· Phase 1/2· Source

• Active, not recruiting

  Amplatzer Amulet LAAO vs. NOAC

  NCT04226547· Source

• Recruiting

  Distribution of Lymph Node Metastases in Esophageal Carcinoma

  NCT03222895· Source

• Active, not recruiting

  Evaluate the Safety and Performance of the AccuCinch® Ventricular Repair System - The CorCinch-EU Study

  NCT03183895· Source

• Active, not recruiting

  Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

  NCT03595592· Phase 3· Source

• Active, not recruiting

  Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

  NCT03366545· Source

• Active, not recruiting

  Development of Novel Clinical Endpoints in Intermediate AMD

  NCT03349801· Source

• Recruiting

  Italian Registry of HIV-1 Infected Patients With Drug-RESistant Virus to Reverse Transcriptase Inhibitors, InteGrasE and Viral Protease.

  NCT04098315· Source

• Recruiting

  Heart Failure and Aortic Stenosis Transcriptome

  NCT03268135· Source

• Active, not recruiting

  A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

  NCT02411448· Phase 3· Source

• Active, not recruiting

  A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

  NCT02912949· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia5 recruiting
• Heart failure4 recruiting
• Liver and biliary tract cancer3 recruiting
• Obesity3 recruiting
• Ulcerative colitis3 recruiting
• Bladder cancer2 recruiting
• Colorectal cancer2 recruiting
• Crohn's disease2 recruiting
• Gastric and esophageal cancer2 recruiting
• HIV2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Alzheimer disease1 recruiting
• Atrial fibrillation1 recruiting
• Cystic fibrosis1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Head and neck cancer1 recruiting
• Hepatitis B1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Myasthenia gravis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  FOCALFLEX (CE Mark) Study

  NCT06271967· Source

• Completed

  A Real-world Study in Participants With Smoldering Multiple Myeloma

  NCT06472778· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Source

• Completed

  A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

  NCT05852691· Phase 2· Source

• Completed

  A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

  NCT05841030· Source

• Withdrawn

  Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients

  NCT04565496· Phase 2· Source

• Completed

  A Study of Vedolizumab in Adults With Crohn's Disease (CD)

  NCT05192863· Source

• Completed

  A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05455684· Phase 3· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Completed

  A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

  NCT05071664· Phase 2· Source

• Completed

  Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients

  NCT04832958· Phase 2· Source

• Recruiting

  Abbott Vascular Medical Device Registry

  NCT04573660· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Completed

  Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

  NCT04082364· Phase 2/3· Source

• Terminated

  An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

  NCT03779113· Phase 1· Source

• Completed

  MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

  NCT03767335· Phase 1· Source

• Completed

  A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

  NCT03734016· Phase 3· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Source

• Completed

  Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449· Phase 3· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

  NCT03126019· Phase 2· Source

• Completed

  Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

  NCT03364153· Phase 2· Source

• Terminated

  A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

  NCT03248492· Phase 2· Source

• Completed

  Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia

  NCT02827617· Source

• Completed

  Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

  NCT02620280· Phase 3· Source

• Completed

  Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver

  NCT02724540· Phase 2· Source

• Completed

  Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

  NCT02283853· Phase 3· Source